Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
- Authors
- Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Nishiyama, Taihei; Chen, Li-Tzong; Kang, Yoon-Koo
- Issue Date
- 7월-2021
- Publisher
- SPRINGER
- Keywords
- ATTRACTION-2; Gastric or gastroesophageal junction cancer; Long-term efficacy; Nivolumab; Treatment beyond progression
- Citation
- GASTRIC CANCER, v.24, no.4, pp.946 - 958
- Indexed
- SCIE
SCOPUS
- Journal Title
- GASTRIC CANCER
- Volume
- 24
- Number
- 4
- Start Page
- 946
- End Page
- 958
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/137239
- DOI
- 10.1007/s10120-021-01173-w
- ISSN
- 1436-3291
- Abstract
- Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with >= 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified. Methods The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by assessing postprogression survival (PPS) after the first event of disease progression. Results Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median follow-up of 38.5 (range 36.1-47.5) months, OS of the nivolumab group was significantly longer compared to the placebo group (median 5.3 vs 4.1 months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 0.50-0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 26.7 months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 5.8 vs 4.5 months; HR [95% CI], 0.69 [0.47-1.01], P = 0.057). In contrast, PPS was similar between both treatment groups in non-TBP patients (median 2.3 vs 2.2 months; HR 0.90, P = 0.42). Conclusions Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.